Published Papers & Misc - YAMAMOTO Masahide

41. Arai A, Sakashita C, Hirose C, Imadome K, Yamamoto M, Jinta M, Fujiwara S, Tomita M, Shimizu N, Morio T, and Miura O.. Hematopoietic stem cell transplantation for adults with EBV-positive T- or NK-cell lymphoproliferative disorders: efficacy and predictive markers Bone Marrow Transplantation. 2016;

42. Emi Uchida, Ken Watanabe, Reina Arai, Masahide Yamamoto, Masayoshi Souri, Tsukasa Osaki, Akitada Ichinose, Osamu Miura, Takatoshi Koyama. Autoimmune Hemorrhaphilia Resulting from Autoantiboy against the A Subunit of Factor XIII. Internal Medicine. 2015.09; 54 (18): 2383-2387.

43. Masahide Yamamoto, Keigo Okada, Hiroki Akiyama, Tetsuya Kurosu, Osamu Miura. Evaluation of the efficacy of maintenance therapy for low-to-intermediate-risk acute promyelocytic leukemia in molecular remission: A retrospective single-institution study. Mol Clin Oncol. 2015.03; 3 (2): 449-453. ( PubMed, DOI )

44. Hiroki Akiyama, Masahide Yamamoto, Chizuko Sakashita, Yoshihiro Umezawa, Tetsuya Kurosu, Naomi Murakami, Osamu Miura. Therapy-related Leukemia with Inv(16)(p13.1q22) and Type D CBFB/MYH11 Developing after Exposure to Irinotecan-containing Chemoradiotherapy. Intern. Med.. 2015; 54 (6): 651-655. ( PubMed, DOI )

45. Toshikage Nagao, Tetsuya Kurosu, Yoshihiro Umezawa, Ayako Nogami, Gaku Oshikawa, Shuji Tohda, Masahide Yamamoto, Osamu Miura. Proliferation and survival signaling from both Jak2-V617F and Lyn involving GSK3 and mTOR/p70S6K/4EBP1 in PVTL-1 cell line newly established from acute myeloid leukemia transformed from polycythemia vera. PLoS ONE. 2014; 9 (1): e84746. ( PubMed, DOI )

46. Naoto Takahashi, Taiichi Kyo, Yasuhiro Maeda, Takashi Sugihara, Kensuke Usuki, Tatsuya Kawaguchi, Noriko Usui, Shinichiro Okamoto, Yokiko Ohe, Shigeki Ohtake, Kunio Kitamura, Masahide Yamamoto, Hirofumi Teshima, Toshiko Motoji, Toshiharu Tamaki, Kenichi Sawada, Kazuma Ohyashiki. Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia. Haematologica. 2012.06; 97 (6): 903-906. ( PubMed, DOI )

47. Naoto Tomita, Masahiro Yokoyama, Wataru Yamamoto, Reina Watanabe, Yutaka Shimazu, Yasufumi Masaki, Saburo Tsunoda, Chizuko Hashimoto, Kayoko Murayama, Takahiro Yano, Rumiko Okamoto, Ako Kikuchi, Kazuo Tamura, Kazuya Sato, Kazutaka Sunami, Hirohiko Shibayama, Rishu Takimoto, Rika Ohshima, Yoshihiro Hatta, Yukiyoshi Moriuchi, Tomohiro Kinoshita, Masahide Yamamoto, Ayumi Numata, Yoshiaki Ishigatsubo, Kengo Takeuchi. Central nervous system event in patients with diffuse large B-cell lymphoma in the rituximab era. Cancer Sci.. 2012.02; 103 (2): 245-251. ( PubMed, DOI )

48. Masahide Yamamoto, Kazuteru Ohashi, Yuka Hirashima, Takeshi Kobayashi, Kazuhiko Kakihana, Hideki Akiyama, Hisashi Sakamaki. Poor outcome of myeloablative conditioned allogeneic bone marrow transplantation for myelofibrosis. Intern. Med.. 2012; 51 (10): 1183-1186. ( PubMed )

49. Yamamoto M, Kakihana K, Ohashi K, Yamaguchi T, Tadokoro K, Akiyama H, Sakamaki H. Serial monitoring of T315I BCR-ABL mutation by Invader assay combined with RT-PCR. Int J Hematol. 2009.05; 89 (4): 482-488. ( PubMed, DOI )

50. Tetsuya Kurosu, Kana Tsuji, Manabu Ohki, Tohru Miki, Masahide Yamamoto, Kazuhiko Kakihana, Takatoshi Koyama, Shuichi Taniguchi, Osamu Miura. A variant-type MLL/SEPT9 fusion transcript in adult de novo acute monocytic leukemia (M5b) with t(11;17)(q23;q25). Int. J. Hematol.. 2008.09; 88 (2): 192-196. ( PubMed, DOI )

51. Kazuhiko Kakihana, Masahide Yamamoto, Mitsuko Iiyama, Osamu Miura. Calmodulin physically interacts with the erythropoietin receptor and enhances Jak2-mediated signaling. Biochem. Biophys. Res. Commun.. 2005.09; 335 (2): 424-431. ( PubMed, DOI )

52. Yamamoto M, Kakihana K, Kurosu T, Murakami N, Miura O. Clonal evolution with inv(11)(p15q22) and NUP98/DDX10 fusion gene in imatinib-resistant chronic myelogenous leukemia. Cancer Genet Cytogenet. 2005.03; 157 (2): 104-108. ( PubMed, DOI )

53. Yamamoto M, Kurosu T, Kakihana K, Mizuchi D, Miura O. The two major imatinib resistance mutations E255K and T315I enhance the activity of BCR/ABL fusion kinase. Biochem Biophys Res Commun. 2004.07; 319 (4): 1272-1275. ( PubMed, DOI )